- Home
- EDF vs IPHA Comparison
EDF vs IPHA Comparison
Compare EDF & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDF
- IPHA
- Stock Information
- Founded
- EDF 2010
- IPHA 1999
- Country
- EDF United States
- IPHA France
- Employees
- EDF N/A
- IPHA N/A
- Industry
- EDF Investment Managers
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- EDF Finance
- IPHA Health Care
- Exchange
- EDF Nasdaq
- IPHA Nasdaq
- Market Cap
- EDF 160.2M
- IPHA 160.1M
- IPO Year
- EDF N/A
- IPHA 2019
- Fundamental
- Price
- EDF $5.15
- IPHA $2.04
- Analyst Decision
- EDF
- IPHA Strong Buy
- Analyst Count
- EDF 0
- IPHA 1
- Target Price
- EDF N/A
- IPHA $11.00
- AVG Volume (30 Days)
- EDF 160.6K
- IPHA 8.3K
- Earning Date
- EDF 01-01-0001
- IPHA 09-17-2025
- Dividend Yield
- EDF 13.14%
- IPHA N/A
- EPS Growth
- EDF N/A
- IPHA N/A
- EPS
- EDF N/A
- IPHA N/A
- Revenue
- EDF N/A
- IPHA $20,831,349.00
- Revenue This Year
- EDF N/A
- IPHA $350.96
- Revenue Next Year
- EDF N/A
- IPHA $32.92
- P/E Ratio
- EDF N/A
- IPHA N/A
- Revenue Growth
- EDF N/A
- IPHA N/A
- 52 Week Low
- EDF $3.51
- IPHA $1.29
- 52 Week High
- EDF $5.50
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- EDF 55.28
- IPHA 44.90
- Support Level
- EDF $5.13
- IPHA $1.90
- Resistance Level
- EDF $5.19
- IPHA $2.16
- Average True Range (ATR)
- EDF 0.05
- IPHA 0.09
- MACD
- EDF -0.00
- IPHA -0.03
- Stochastic Oscillator
- EDF 69.23
- IPHA 32.17
About EDF Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest
Virtus Stone Harbor Emerging Markets Income Fund is a closed-end management investment company. Its investment objective is to maximize total return, which consists of income from its investments and capital appreciation. The Fund normally will invest at least 80% of its net assets (plus any borrowings for investment purposes) in emerging markets securities.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.